Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge

J Pharm Sci. 1992 Jun;81(6):541-2. doi: 10.1002/jps.2600810614.


A sustained-release formulation of hydralazine was manufactured by binding hydralazine to an ion-exchange resin and coating the drug-resin complex with a semipermeable membrane. Because the sustained-release characteristics are due in part to displacement of drug from the drug-resin complex by gastrointestinal ions, the stability of the sustained-release formulation could be compromised if challenged by a high concentration of ions. In this study, 12 healthy male volunteers participated in a two-way crossover trial that was designed to test the bioavailability and release of drug from the sustained-release formulation both with and without concomitant ingestion of a solution of KCl. Blood samples were collected over a 14-h period after administration of either treatment. Analysis of whole blood for hydralazine and comparison of the values of the area under the curve of the concentration of hydralazine versus time, the maximum concentration of hydralazine, and the time to reach the maximum concentration between the two experimental groups showed that KCl had no influence on the bioavailability or release characteristics of hydralazine from the sustained-release formulation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Biological Availability
  • Delayed-Action Preparations
  • Humans
  • Hydralazine / administration & dosage
  • Hydralazine / pharmacokinetics*
  • Ion Exchange Resins
  • Male
  • Potassium / pharmacology*


  • Delayed-Action Preparations
  • Ion Exchange Resins
  • Hydralazine
  • Potassium